PL81650B1 - - Google Patents

Download PDF

Info

Publication number: PL81650B1
Authority: PL; Poland
Prior art keywords: radical; formula; methyl; carbon atoms; propyl
Prior art date: 1970-02-16

Application number

PL14594771A

Other languages

English (en)

Polish (pl)

Original Assignee

Imperial Chemical Industries Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1970-02-16

Filing date

1971-02-01

Publication date

1975-08-30

1971-02-01 Application filed by Imperial Chemical Industries Limited filed Critical Imperial Chemical Industries Limited

1975-08-30 Publication of PL81650B1 publication Critical patent/PL81650B1/pl

Links

150000001875 compounds Chemical class 0.000 claims description 27
-1 acyl radicals Chemical class 0.000 claims description 26
125000004432 carbon atom Chemical group C* 0.000 claims description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 13
YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical class BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 claims description 13
238000000034 method Methods 0.000 claims description 11
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
150000003254 radicals Chemical class 0.000 claims description 8
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 4
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 4
JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
238000010438 heat treatment Methods 0.000 claims description 4
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 4
ZSBDPRIWBYHIAF-UHFFFAOYSA-N n-acetylacetamide Chemical compound CC(=O)NC(C)=O ZSBDPRIWBYHIAF-UHFFFAOYSA-N 0.000 claims description 4
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 3
125000000217 alkyl group Chemical group 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
238000006243 chemical reaction Methods 0.000 claims description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 3
239000000376 reactant Substances 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 2
WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 claims description 2
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
239000002904 solvent Substances 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
150000002367 halogens Chemical group 0.000 claims 1
UJTMLNARSPORHR-UHFFFAOYSA-N oc2h5 Chemical compound C=C=[O+] UJTMLNARSPORHR-UHFFFAOYSA-N 0.000 claims 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 10
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
125000000468 ketone group Chemical group 0.000 description 8
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000003480 eluent Substances 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000000377 silicon dioxide Substances 0.000 description 6
239000007858 starting material Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000010992 reflux Methods 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
PKWIYNIDEDLDCJ-UHFFFAOYSA-N guanazole Chemical compound NC1=NNC(N)=N1 PKWIYNIDEDLDCJ-UHFFFAOYSA-N 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
208000009079 Bronchial Spasm Diseases 0.000 description 2
206010006482 Bronchospasm Diseases 0.000 description 2
241000700198 Cavia Species 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
229930194542 Keto Natural products 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
SRNKZYRMFBGSGE-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CN=C21 SRNKZYRMFBGSGE-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000002253 acid Substances 0.000 description 2
XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
230000003266 anti-allergic effect Effects 0.000 description 2
235000019789 appetite Nutrition 0.000 description 2
238000009835 boiling Methods 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010023644 Lacrimation increased Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
BQOWUDKEXDCGQS-UHFFFAOYSA-N [CH]1CCCC1 Chemical compound [CH]1CCCC1 BQOWUDKEXDCGQS-UHFFFAOYSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000036528 appetite Effects 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
238000010908 decantation Methods 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
230000004317 lacrimation Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
DDCYOMQDEGIFNS-UHFFFAOYSA-N triazolo[4,5-d]pyrimidin-5-one Chemical class O=C1N=CC2=NN=NC2=N1 DDCYOMQDEGIFNS-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL14594771A 1970-02-16 1971-02-01 PL81650B1 (2)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB738670A GB1284485A (en)	1970-02-16	1970-02-16	Process for the manufacture of triazolopyrimidine derivatives

Publications (1)

Publication Number	Publication Date
PL81650B1 true PL81650B1 (2)	1975-08-30

Family

ID=9832135

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14594771A PL81650B1 (2)	1970-02-16	1971-02-01

Country Status (8)

Country	Link
AT (1)	AT303726B (2)
CA (1)	CA955255A (2)
CH (1)	CH544765A (2)
ES (1)	ES388311A1 (2)
GB (1)	GB1284485A (2)
HU (1)	HU163720B (2)
PL (1)	PL81650B1 (2)
SU (1)	SU367604A3 (2)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4614743A (en) *	1983-12-27	1986-09-30	Schering Corporation	Methods of treating pain and inflammation with 4,7-dimethyl-2-(4-pyridinyl)-1,2,4,-triazolo[1,5-a]pyrimidin-5(4H)-one or the pharmaceutically acceptable salts or solvates thereof
CN116178375B (zh) *	2023-02-24	2024-09-20	重庆文理学院	一种三唑并嘧啶化合物及其合成方法和应用

1970
- 1970-02-16 GB GB738670A patent/GB1284485A/en not_active Expired
1971
- 1971-02-01 CA CA104,198A patent/CA955255A/en not_active Expired
- 1971-02-01 PL PL14594771A patent/PL81650B1/pl unknown
- 1971-02-10 SU SU1619886A patent/SU367604A3/ru active
- 1971-02-16 ES ES388311A patent/ES388311A1/es not_active Expired
- 1971-02-16 HU HUIE000431 patent/HU163720B/hu unknown
- 1971-02-16 CH CH221371A patent/CH544765A/de not_active IP Right Cessation
- 1971-02-16 AT AT132471A patent/AT303726B/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA955255A (en)	1974-09-24
ES388311A1 (es)	1973-05-01
SU367604A3 (2)	1973-01-23
CH544765A (de)	1973-11-30
AT303726B (de)	1972-12-11
GB1284485A (en)	1972-08-09
HU163720B (2)	1973-10-27

Publication	Publication Date	Title
GB2092145A (en)	1982-08-11	Substituted chromans
US4087423A (en)	1978-05-02	Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyridines
PL89008B1 (2)	1976-10-30
KR900005836B1 (ko)	1990-08-13	1,2,4-트리아조로[4,3-c]피리미딘
US3689488A (en)	1972-09-05	Certain s-triazolo 1,5-a pyrimidines
CA1054600A (en)	1979-05-15	Amino derivatives of imidazo (4,5-b) pyridines
US4028370A (en)	1977-06-07	Novel pyrazolo [1,5-a]pyridines
PL109346B1 (en)	1980-05-31	Method of producing new derivatives of recemic eventually optically active condensed pyrimidines
CA1203801A (en)	1986-04-29	Piperazine derivatives, their production and pharmaceutical compositions containing them
EP0055068B1 (en)	1984-10-17	Quinolone derivatives and their use as pharmaceuticals
PL81650B1 (2)	1975-08-30
Coates et al.	1993	Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: Analogs of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase
US3669950A (en)	1972-06-13	DIPYRAZOLO{8 3,4-b:3,4d{9 -PYRIDIN-3-ONES
US4066645A (en)	1978-01-03	Derivatives of pyrazolo [1,5-a]pyrido[3,4-e]pyrimidine
US3929812A (en)	1975-12-30	Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters
NZ206224A (en)	1986-09-10	2-piperazinyl(or homopyperazinyl)-quinazoline derivatives and pharmaceutical compositions
EP0273321B1 (en)	1992-04-22	7-bromo-beta-carboline compound and method for producing same
CA1050027A (en)	1979-03-06	Derivatives of pyrazolo (3,4-b) thieno (2,3-d) pyridine-2-carboxylic acids
CA1073905A (en)	1980-03-18	Pyrazolo (1,5-a) pyrido (3,2-e) pyrimidine-7-carboxylic acid derivatives
GB2096143A (en)	1982-10-13	Imidazo(1,2-a)quinoline derivatives
PL75399B3 (en)	1974-12-31	Certain 2,4-diamino-5-benzyl-6-alkylthiopyrimidines[us3822264a]
US3962262A (en)	1976-06-08	1,8-naphthyridine compounds
US3773949A (en)	1973-11-20	Certain s-triazolo(1,5-a)pyrimidines for preventing bronchospasm or reducing body fat
EP1098882B1 (en)	2004-08-25	A process for preparing benzocycloheptapyridin-11-ones
US4237289A (en)	1980-12-02	2,7-Diamino-8-methyl-5-substituted pyrido{2,3-d}pyrimidin-6-ones